U.S. Markets open in 6 hrs, 30 mins
| Symbol | Value | Change | Percentage Change |
|---|---|---|---|
| DJIA | 11,384.21 | 152.25 | 1.36% |
| NASDAQ | 2,294.44 | 51.12 | 2.28% |
| S&P 500 | 1,273.70 | 21.39 | 1.71% |
| Day Low 09:33 AM EDT | 13.79 | |
|---|---|---|
| Day High 03:53 PM EDT | 15.75 |
|
| Range | 1.96 | |
| Volume | 977,260 | |
| 30-Day Avg. Vol. | 493,000 |
|
| Difference | 98.23% | |
| Market Cap. | 464.74 M | |
| Change | 40.82 M | |
| Shares Out. | 30.02 M | |
| Percent Traded | 3.26% | |
| Revenue | 75.64 M | |
| Earnings | -43.68 M | |
| EPS (TTM) | -1.72 |
| 52-Wk Low 3/12/08 | 4.33 | |
|---|---|---|
| 52-Wk High 9/5/07 | 26.10 |
|
| Range | 21.77 | |
| Prev. Close 7/7/08 | 14.12 | |
| Today's Open | 14.05 | |
| Change | -0.50% | |
| Dividend (TTM) | 0.00 | |
| Div. Yield (TTM) | 0.00% |
|
| Beta | 2.7472 | |
| P/E Ratio (TTM) | — | |
| P/E Ratio (Fwd.) | -12.00 |
Progenics Pharmaceuticals is taking a proactive approach to fighting serious diseases such as HIV and cancer. The biotech company won its first FDA approval in 2008 with Relistor (methylnatrexone), which ... View Full Description
| Earnings/Share(EPS) | Estimate | Actual | Difference |
|---|---|---|---|
| 2 Quarters Ago | -0.491 12/31/07 | -0.53 12/31/07 |
-0.039
Missed
|
| Last Quarter | -0.471 3/31/08 | -0.52 3/31/08 |
-0.049
Missed
|
| Quarterly - 03/31/2008 | Annual - 2007 | |
|---|---|---|
| Total Revenue | 14.76 M | 75.65 M |
| Gross Profit | -6.38 M | 72.62 M |
| Operating Income | -17.44 M | -51.46 M |
| Net Income | -15.48 M | -43.69 M |
